Suppr超能文献

使用无线动力胶囊研究胰高血糖素样肽-1受体激动剂对全肠道胃肠动力的影响:一项描述性单中心病例系列研究

Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.

作者信息

Cymbal Michael, Naseem Zehra, Hoxha Din, Garg Samita

机构信息

Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.

Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

出版信息

ACG Case Rep J. 2025 Aug 4;12(8):e01789. doi: 10.14309/crj.0000000000001789. eCollection 2025 Aug.

Abstract

This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule testing for constipation or gastroparesis to assess gastric, small bowel, and colonic transit times. Delayed gastric emptying time was observed in 80% of patients, whereas delayed whole-gut transit time was noted in 44% of patients. The 3 patients on semaglutide (1 mg) had the longest gastric emptying time, delayed whole-gut transit time, and were the only patients with delayed small bowel transit time. Although limited by retrospective observation, our findings are consistent with the effects of GLP-1RAs on gastric motility delay and suggest an impact on whole-gut motility. With the expanding use of GLP-1RAs, these findings underscore the need for prospective studies using emerging motility technologies to further characterize the motility effects both during treatment and after cessation, thereby guiding evidence-based clinical decision-making.

摘要

本回顾性病例系列研究使用无线动力胶囊测试,探究胰高血糖素样肽-1受体激动剂(GLP-1RAs)对全肠道胃肠动力的影响。我们分析了10例接受GLP-1RAs治疗的患者,这些患者因便秘或胃轻瘫接受了无线动力胶囊测试,以评估胃、小肠和结肠的转运时间。80%的患者观察到胃排空延迟,而44%的患者全肠道转运时间延迟。3例使用司美格鲁肽(1毫克)的患者胃排空时间最长,全肠道转运时间延迟,且是仅有的小肠转运时间延迟的患者。尽管本研究受回顾性观察的限制,但我们的研究结果与GLP-1RAs对胃动力延迟的作用一致,并提示其对全肠道动力有影响。随着GLP-1RAs的使用不断增加,这些研究结果强调需要采用新兴动力技术进行前瞻性研究,以进一步明确治疗期间和停药后的动力效应,从而指导基于证据的临床决策。

相似文献

1
Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.
ACG Case Rep J. 2025 Aug 4;12(8):e01789. doi: 10.14309/crj.0000000000001789. eCollection 2025 Aug.
3
Impact of Constipation Therapies on Severity of Gastroparesis and Constipation Symptoms in Relation to Gastric and Colonic Transit.
Neurogastroenterol Motil. 2025 Jun;37(6):e70013. doi: 10.1111/nmo.70013. Epub 2025 Mar 3.
4
Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit.
Clin Gastroenterol Hepatol. 2022 Mar;20(3):546-558.e5. doi: 10.1016/j.cgh.2020.10.045. Epub 2020 Oct 28.
5
Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy.
Endoscopy. 2025 Feb;57(2):126-133. doi: 10.1055/a-2419-3875. Epub 2024 Oct 10.
6
The Assessment of Gastrointestinal Transit by the Atmo Capsule: A Comparison With the SmartPill Capsule.
Clin Gastroenterol Hepatol. 2025 Aug;23(9):1633-1641.e8. doi: 10.1016/j.cgh.2024.12.013. Epub 2025 Jan 30.
8
GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis.
Pharmacotherapy. 2025 Apr;45(4):211-219. doi: 10.1002/phar.70007. Epub 2025 Feb 23.
9
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
J Clin Endocrinol Metab. 2024 Dec 18;110(1):1-15. doi: 10.1210/clinem/dgae719.

本文引用的文献

2
Longitudinal Analysis of Obesity Drug Use and Public Awareness.
JAMA Netw Open. 2025 Jan 2;8(1):e2457232. doi: 10.1001/jamanetworkopen.2024.57232.
3
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
Nat Rev Cardiol. 2023 Jul;20(7):463-474. doi: 10.1038/s41569-023-00849-3. Epub 2023 Mar 28.
4
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
Circulation. 2022 Dec 13;146(24):1882-1894. doi: 10.1161/CIRCULATIONAHA.122.059595. Epub 2022 Dec 12.
5
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.
7
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.
8
Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis.
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1770-1779.e2. doi: 10.1016/j.cgh.2018.11.063. Epub 2018 Dec 14.
9
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. Epub 2018 Feb 1.
10
Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.
J Clin Endocrinol Metab. 2018 Feb 1;103(2):575-585. doi: 10.1210/jc.2017-02006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验